Value of brief hematological characteristics in differentiating carcinoembryonic-antigen-negative colorectal cancer from benign colorectal diseases

Figure 1 Comparison of hemoglobin-to-red blood cell distribution width ratio, lymphocyte-to-red blood cell distribution width ratio, and platelet-to-lymphocyte ratio between the cancer stage and benign colorectal diseases groups. A: Hemoglobin-to-red blood cell distribution width ratio (HRR) in tumor-node-metastasis (TNM) stage and benign colorectal diseases groups; B: HRR in T stage and benign colorectal diseases groups; C: HRR in N stage and benign colorectal diseases groups; D: HRR in M stage and benign colorectal diseases groups; E: Lymphocyte-to-red blood cell distribution width ratio (LRR) in TNM stage and benign colorectal diseases groups; F: LRR in T stage and benign colorectal diseases groups; G: LRR in N stage and benign colorectal diseases groups; H: LRR in M stage and benign colorectal diseases groups; I: Platelet-to-lymphocyte ratio (PLR) in TNM stage and benign colorectal diseases groups; J: PLR in T stage and benign colorectal diseases groups; K: PLR in N stage and benign colorectal diseases groups; L: PLR in M stage and benign colorectal diseases groups. ^aP < 0.05 and ^aP < 0.01 vs benign colorectal diseases group; ^bP < 0.05 vs stage T1 + T2; ^cP < 0.05 vs stage M0; HRR: Hemoglobin-to-red blood cell distribution width ratio; LRR: Lymphocyte-to-red blood cell distribution width ratio; PLR: Platelet-to-lymphocyte ratio.

Figure 2 Correlation between hematological parameters and clinic-pathological features in carcinoembryonic-antigen-negative colorectal cancer patients. A: Correlation between hemoglobin-to-red blood cell distribution width ratio and T stage; B: Correlation between lymphocyte-to-red blood cell distribution width ratio (LRR) and T stage; C: Correlation between LRR and M stage; D: Correlation between platelet-to-lymphocyte ratio and T stage. HRR: Hemoglobin-to-red blood cell distribution width ratio; LRR: Lymphocyte-to-red blood cell distribution width ratio; PLR: Platelet-to-lymphocyte ratio.

Figure 3 Receiver operating characteristic evaluation of the value of hematological parameters for diagnosis of patients with carcinoembryonic-antigen-negative colorectal cancer. A: Receiver operating characteristic (ROC) curve analysis of carcinoembryonic antigen (CEA), hemoglobin-to-red blood cell distribution width ratio (HRR), lymphocyte-to-red blood cell distribution width ratio (LRR), and platelet-to-lymphocyte ratio (PLR); B: ROC curve analysis of HRR + CEA, HRR + PLR, LRR + CEA, PLR + CEA, and HRR + PLR + LRR + CEA. HRR: Hemoglobin-to-red blood cell distribution width ratio; LRR: Lymphocyte-to-red blood cell distribution width ratio; PLR: Platelet-to-lymphocyte ratio; CEA: Carcinoembryonic antigen.